Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats

Background/Objectives: Feline panleukopenia, caused by FPV, is a highly contagious disease in cats. Current vaccines face challenges including complex production, high cost, and safety risks. Developing safer, more efficient alternatives is crucial. This study aimed to produce FPV virus-like particl...

Full description

Saved in:
Bibliographic Details
Main Authors: Tongyan Wang, Hongchao Wu, Yanwei Wang, Yang Guan, Yujiao Cao, Lulu Wang, Mengyue Wang, Feifei Tan, Wenqiang Pang, Kegong Tian
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/13/7/684
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849251904263028736
author Tongyan Wang
Hongchao Wu
Yanwei Wang
Yang Guan
Yujiao Cao
Lulu Wang
Mengyue Wang
Feifei Tan
Wenqiang Pang
Kegong Tian
author_facet Tongyan Wang
Hongchao Wu
Yanwei Wang
Yang Guan
Yujiao Cao
Lulu Wang
Mengyue Wang
Feifei Tan
Wenqiang Pang
Kegong Tian
author_sort Tongyan Wang
collection DOAJ
description Background/Objectives: Feline panleukopenia, caused by FPV, is a highly contagious disease in cats. Current vaccines face challenges including complex production, high cost, and safety risks. Developing safer, more efficient alternatives is crucial. This study aimed to produce FPV virus-like particles (VLPs) using a recombinant baculovirus system expressing the VP2 gene and evaluate their immunogenicity and protective efficacy in cats. Methods: Sf9 insect cells were infected with recombinant baculovirus to express VP2 protein. The VP2 protein was purified using ultrafiltration and size-exclusion chromatography (SEC). Dynamic light scattering (DLS) and transmission electron microscopy (TEM) confirmed the assembly of VLPs. Twenty healthy cats were randomly divided into four groups; three groups received different doses (5 μg, 15 μg, and 45 μg) of FPV VLP vaccine, while the fourth group served as the control group immunized with PBS. Blood samples were collected on day 21 to measure hemagglutination inhibition (HI) and virus-neutralizing (VN) antibody responses. Cats in the 15 μg dose group were challenged with virulent FPV strain 708 on day 21, and clinical signs and white blood cell counts were monitored for 10 days. Results: Immunized cats exhibited significantly higher HI and VN antibody titers compared to controls. After challenge, vaccinated cats showed no clinical signs of disease, and their white blood cell counts remained stable. In contrast, control cats developed severe symptoms and experienced significant leukopenia. Conclusions: The FPV VLP vaccine generated in this study are highly immunogenic and provide effective protection against virulent FPV challenge, demonstrating their potential as a safer vaccine candidate for feline panleukopenia.
format Article
id doaj-art-5ef94ffee75243f4961efe9d662ec144
institution Kabale University
issn 2076-393X
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj-art-5ef94ffee75243f4961efe9d662ec1442025-08-20T03:56:46ZengMDPI AGVaccines2076-393X2025-06-0113768410.3390/vaccines13070684Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in CatsTongyan Wang0Hongchao Wu1Yanwei Wang2Yang Guan3Yujiao Cao4Lulu Wang5Mengyue Wang6Feifei Tan7Wenqiang Pang8Kegong Tian9College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, ChinaCollege of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaNational Research Center for Veterinary Medicine, Road Cuiwei, High-Tech District, Luoyang 471003, ChinaBackground/Objectives: Feline panleukopenia, caused by FPV, is a highly contagious disease in cats. Current vaccines face challenges including complex production, high cost, and safety risks. Developing safer, more efficient alternatives is crucial. This study aimed to produce FPV virus-like particles (VLPs) using a recombinant baculovirus system expressing the VP2 gene and evaluate their immunogenicity and protective efficacy in cats. Methods: Sf9 insect cells were infected with recombinant baculovirus to express VP2 protein. The VP2 protein was purified using ultrafiltration and size-exclusion chromatography (SEC). Dynamic light scattering (DLS) and transmission electron microscopy (TEM) confirmed the assembly of VLPs. Twenty healthy cats were randomly divided into four groups; three groups received different doses (5 μg, 15 μg, and 45 μg) of FPV VLP vaccine, while the fourth group served as the control group immunized with PBS. Blood samples were collected on day 21 to measure hemagglutination inhibition (HI) and virus-neutralizing (VN) antibody responses. Cats in the 15 μg dose group were challenged with virulent FPV strain 708 on day 21, and clinical signs and white blood cell counts were monitored for 10 days. Results: Immunized cats exhibited significantly higher HI and VN antibody titers compared to controls. After challenge, vaccinated cats showed no clinical signs of disease, and their white blood cell counts remained stable. In contrast, control cats developed severe symptoms and experienced significant leukopenia. Conclusions: The FPV VLP vaccine generated in this study are highly immunogenic and provide effective protection against virulent FPV challenge, demonstrating their potential as a safer vaccine candidate for feline panleukopenia.https://www.mdpi.com/2076-393X/13/7/684feline parvovirusvirus-like particles (VLPs)vaccine
spellingShingle Tongyan Wang
Hongchao Wu
Yanwei Wang
Yang Guan
Yujiao Cao
Lulu Wang
Mengyue Wang
Feifei Tan
Wenqiang Pang
Kegong Tian
Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
Vaccines
feline parvovirus
virus-like particles (VLPs)
vaccine
title Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
title_full Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
title_fullStr Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
title_full_unstemmed Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
title_short Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats
title_sort virus like particle vaccine for feline panleukopenia immunogenicity and protective efficacy in cats
topic feline parvovirus
virus-like particles (VLPs)
vaccine
url https://www.mdpi.com/2076-393X/13/7/684
work_keys_str_mv AT tongyanwang viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT hongchaowu viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT yanweiwang viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT yangguan viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT yujiaocao viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT luluwang viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT mengyuewang viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT feifeitan viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT wenqiangpang viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats
AT kegongtian viruslikeparticlevaccineforfelinepanleukopeniaimmunogenicityandprotectiveefficacyincats